<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552641</url>
  </required_header>
  <id_info>
    <org_study_id>TIMESO</org_study_id>
    <nct_id>NCT02552641</nct_id>
  </id_info>
  <brief_title>Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole</brief_title>
  <official_title>Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is assess whether the various forms of triple regimen of&#xD;
      administration of treatment of Helicobacter pylori (before meals (fasting), after meals, and&#xD;
      any independent mealtime) influence the rate of eradication of this bacterium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase IV, open, randomized, prospective study.&#xD;
&#xD;
        -  Length of experience: 180 days.&#xD;
&#xD;
        -  06 visits.&#xD;
&#xD;
        -  Evaluation of the efficacy of differences regimens of administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of H pylori eradication</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects in each of the forms of triple therapy administration and compare them</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">363</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food effect</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_label>Test 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_label>Test 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_label>Test 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarythromycin</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_label>Test 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants of both sexes;&#xD;
&#xD;
          -  Age greater than or equal to 18 and less than or equal to 50 years;&#xD;
&#xD;
          -  Participant diagnosed with type dyspepsia epigastric pain carriers of Helicobacter&#xD;
             pylori infection, according to the classification of ROME III;&#xD;
&#xD;
          -  Ability to understand and consent to participate in this clinical study, manifested by&#xD;
             reading, understanding and signing of the Informed Consent (IC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of clinical observation (clinical evaluation / physical) that is&#xD;
             interpreted by the investigator as a medical risk to participate in the clinical&#xD;
             trial;&#xD;
&#xD;
          -  Any laboratory examination found that the investigator doctor considers a risk to the&#xD;
             research participant for their participation in the clinical trial;&#xD;
&#xD;
          -  Known hypersensitivity to the drug components used during the study;&#xD;
&#xD;
          -  Women in pregnancy or breastfeeding period;&#xD;
&#xD;
          -  Women in reproductive age who do not agree to use acceptable methods of contraception&#xD;
             (oral contraceptives, injectable contraceptive, IUD, hormonal implants, barrier&#xD;
             methods, abstinence, hormonal patch and tubal ligation); except surgically sterile&#xD;
             (bilateral oophorectomy or hysterectomy);&#xD;
&#xD;
          -  Participating in the research that has participated in clinical trial protocols in the&#xD;
             last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J),&#xD;
             unless the investigator considers that there may be direct benefit to it;&#xD;
&#xD;
          -  Party that has some kinship to the second degree or bond with employees or employees&#xD;
             of Sponsor and Research Center;&#xD;
&#xD;
          -  Patients with predominant symptoms of reflux or irritable bowel syndrome, warning&#xD;
             symptoms, peptic ulcer history or previous surgery in the upper segment of the&#xD;
             gastrointestinal tract;&#xD;
&#xD;
          -  Patients with prior treatment history of eradication of Helicobacter pylori;&#xD;
&#xD;
          -  Patients with kidney, liver or heart failure;&#xD;
&#xD;
          -  Patients with past or current history of alcohol abuse;&#xD;
&#xD;
          -  Patients with a history of use of antibiotics or bismuth in the 4 weeks prior to study&#xD;
             entry, PPIs or H2 blockers, NSAIDs or aspirin in the last two weeks;&#xD;
&#xD;
          -  Patients whose endoscopy show changes except hyperemic gastritis, erosive gastritis&#xD;
             den considering the maximum of 5 erosions in this location or hiatal hernia;&#xD;
&#xD;
          -  Patients whose ultrasonography show hepato-biliopancreatic changes except steatosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Decio Chinzon, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Ecclissato, Md</last_name>
    <phone>55.19.38879433</phone>
    <email>christina.ecclissato@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Decio Chinzon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Decio Chinzon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

